Further processing options
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial
Saved in:
Journal Title: | Clinical Cancer Research |
---|---|
Authors and Corporations: | , , , , , , , , , , , , , , |
In: | Clinical Cancer Research, 25, 2019, 2, p. 771-783 |
Type of Resource: | E-Article |
Language: | English |
published: |
American Association for Cancer Research (AACR)
|
Subjects: |